| Bioactivity | Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1)[1]. | |||||||||
| Target | CB2 | |||||||||
| Name | Vicasinabin | |||||||||
| CAS | 1433361-02-4 | |||||||||
| Formula | C15H22N10O | |||||||||
| Molar Mass | 358.40 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Jean-Michel Adam, et al. Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives. Patent US20130116236A1. |
Vicasinabin
CAS: 1433361-02-4 F: C15H22N10O W: 358.40
Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the r
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.